Drug Patents owned by Gilead
1. List of Letairis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377933 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(4 years from now) | |
| US9474752 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(4 years from now) | |
| US9549926 | GILEAD | Compositions and methods of treating pulmonary hypertension |
Oct, 2031
(8 years from now) | |
Drugs and Companies using AMBRISENTAN ingredient
Market Authorisation Date: 15 June, 2007
Treatment: For the treatment of pulmonary hypertension (pah) in combination with tadalafil; For the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of ambrisentan to tadalafil is about 1:2 to about 1:3
Dosage: TABLET;ORAL
LETAIRIS family patents
17
United States
4
European Union
3
Australia
3
Japan
3
Hungary
2
Korea, Republic of
2
Poland
2
Spain
2
Cyprus
2
Slovenia
2
Portugal
2
EA
2
New Zealand
2
Canada
2
Denmark
1
Hong Kong
1
RS
1
Brazil
1
Lithuania
1
Luxembourg
1
Mexico
1
Argentina
1
South Africa
1
China
1
Croatia
1
Taiwan, Province of China
2. List of Truvada drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8592397 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(11 months from now) | |
| US9457036 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(11 months from now) | |
| US9744181 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(11 months from now) | |
| US8716264 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(11 months from now) | |
Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 02 August, 2004
Treatment: Treatment of hiv; Method of treatment of adults infected with hiv-1; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv infection
Dosage: TABLET;ORAL
TRUVADA family patents
15
United States
8
Japan
4
Norway
4
European Union
3
Korea, Republic of
3
Australia
3
Argentina
3
China
2
Poland
2
EA
2
Croatia
2
Canada
2
Taiwan, Province of China
1
Austria
1
Hong Kong
1
Brazil
1
AP
1
Ukraine
1
Spain
1
Germany
1
Israel
1
Cyprus
1
Mexico
1
Slovenia
1
South Africa
1
Portugal
1
Iceland
1
New Zealand
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic